My watch list  

366 Current news from israel

matching the following criteria

Recipharm acquires OnTarget Chemistry and extends its offering into preclinical development services


Recipharm announces that it has completeted the acquisition of OnTarget Chemistry in Uppsala, Sweden. OnTarget Chemistry is a fast growing CRO company with a turnover in 2014 of close to SEK 29 million that is specialized in medicinal chemistry offering synthesis and analytical services which ...


Recipharm wins SwedenBIO Award


The winner of the ninth annual SwedenBIO Award was announced on 4th June. This year Recipharm AB was honoured for its efforts and contribution to Sweden life science during the past year.The citation reads: "Recipharm has purposefully and with great skill built a solid organisation with a ...


Recipharm appoints Chief Strategy Officer


Recipharm announced that it has appointed Jean-François Hilaire to the new position of Chief Strategy Officer to join Recipharm’s Group Management Team.Jean-François Hilaire is a pharmacist and graduated from the university of Bordeaux and alumni of the CEDEP General Manager Program (campus ...


"Hidden" fragrance compound can cause contact allergy


Linalyl acetate, a fragrance chemical that is one of the main constituents of the essential oil of lavender, is not on the list of allergenic compounds pursuant to the EU Cosmetics Directive. Thus, it does not need to be declared on cosmetic products sold within the EU. Recent studies at the ...


Are antidepressants more effective than usually assumed?


Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to ...


Recipharm makes strategic investment in Synthonics


Recipharm announced that it has made an equity investment in Synthonics Inc and purchased $2.0 million of preferred stock in the company.A further $2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016. In ...


Pharmalink announces positive results in Phase 2b trial of Nefecon


Pharmalink AB announced that the NEFIGAN Trial of Nefecon® for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint. The NEFIGAN Trial is a Phase 2b randomized ...


Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe


Infant Bacterial Therapeutics (IBT), subsidiary of BioGaia, is in the early stages of developing a drug to prevent necrotizing enterocolitis (NEC) which is a rare and fatal disease that affects premature infants. IBT has now obtained the Orphan Drug Designation for the prevention of NEC in ...


Amyloid formation may link Alzheimer disease and type 2 diabetes


The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how ...


Xiapex approved by the EU Commission for the treatment of Peyronie's disease


Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the EU Commission has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's ...


Page 1 From 37
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE